Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging

Fig. 1

Dasatinib treatment decreases phosphorylated Src (pSrc) (Y416) and phosphorylated human epidermal growth factor receptor 2 (pHER2) (Y-1221) protein levels in vitro. BT-474 (a) or JIMT-1 (b) cells were treated with increasing concentrations of dasatinib for 72 h to achieve half maximal inhibitory concentration (IC50) values of 1.3 ± 0.12 μM and 0.22 ± 0.09 μM, respectively. BT-474 cells (c) and JIMT-1 (d) were treated with the IC50 dasatinib up to 48 h and western blots were performed for HER2, Src, pSrc (Y416), and pHER2 (Y1221/1222). Densitometry results are shown as the ratio of target protein/glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Back to article page
\